Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study

被引：0
|
作者：
Estévez, LG
Adrover, E
Barnadas, A
Cuevas, JM
Seguí, MA
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [31] Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients.
    Coskun, HS
    Er, O
    Ozkan, M
    Eser, B
    Altinbas, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [32] Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast Group
    von Minckwitz, G
    Raab, G
    Caputo, A
    Schütte, M
    Hilfrich, F
    Blohmer, JU
    Gerber, B
    Costa, SD
    Merkle, E
    Eidtmann, H
    Lampe, D
    Jackisch, C
    du Bois, A
    Kaufmann, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2676 - 2685
  • [33] Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
    Vriens, B. E. P. J.
    Aarts, M. J. B.
    de Vries, B.
    van Gastel, S. M.
    Wals, J.
    Smilde, T. J.
    van Warmerdam, L. J. C.
    de Boer, M.
    van Spronsen, D. J.
    Borm, G. F.
    Tjan-Heijnen, V. C. G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3102 - 3110
  • [34] A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27
    Bear, HD
    Anderson, S
    Smith, RE
    Robidoux, A
    Kahlenberg, MS
    Margolese, RG
    Dakhil, SR
    Pajon, ER
    Hoehn, JL
    Mamounas, EP
    Geyer, CE
    Julian, TB
    Wolmark, N
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S16
  • [35] Primary systemic chemotherapy for operable breast cancer with docetaxel followed by cyclophosphamide, epirubicin, and fluorauracil (DOC-CEF)
    Kikawa, Y.
    Masai, Y.
    Hashimoto, T.
    Nakamoto, Y.
    Nishikawa, H.
    Takahara, S.
    Suwa, H.
    Tachibana, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Safety analysis of docetaxel (T) and doxorubicin (A) followed by sequential capecitabine (X) as adjuvant chemotherapy of patients with node-positive operable breast cancer (BC).
    Mayordomo, JI
    Madroñal, C
    Garcia-Lopez, MJ
    Burillo, MA
    Perez, V
    Janariz, J
    Murillo, L
    Andres, R
    Lara, R
    Lambea, J
    Sanz, IAJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 80S - 80S
  • [37] Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer
    Jacot, William
    Bibeau, Frederic
    Gourgou-Bourgade, Sophie
    Gutowski, Marian
    Colombo, Pierre-Emmanuel
    Bleuse, Jean-Pierre
    Kramar, Andrew
    Romieu, Gilles
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 544 - 549
  • [38] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
    Wu, Xian
    Ye, Chaoran
    Wang, Xingmeng
    Cai, Ruyu
    Yang, Junzhe
    Yu, Xiafei
    Zhou, Yi
    Shen, Li
    Zhu, Yanhui
    Liu, Xiaoan
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1517 - 1527
  • [40] Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
    Heller, W.
    Mazhar, D.
    Ward, R.
    Sinnett, H. D.
    Lowdell, C.
    Phillips, R.
    Shousha, S.
    Fayaz, A.
    Palmieri, C.
    Coombes, R. C.
    ONCOLOGY REPORTS, 2007, 17 (01) : 253 - 259
12345